Jim Catto

🚀 Exciting announcement!

⭐️ Join us at #BAUS25 for our special session on Monday, 16 June!

🕓 16:30 - 16:45
📍 Charter 3

📢 We are thrilled to welcome our keynote speaker, Freddie Hamdy, who will discuss, "The Challenge of Misinformation"!

#BURSTatBAUS #UroSoMe @bausurology.bsky.social

An important (very short) film from Steve McQueen - don’t be embarrassed to talk about #ProstateCancer. Can effect all men but there’s a higher risk for black men.

www.embarrassedfilm.org

It’ll take less than 2 mins of your time to watch.
An inspiring talk at #BAUS25

Prostate cancer: Rapid at-home PSA tests spark concerns Testing for PSA protein can indicate whether a man is at risk of prostate cancer.

Inaccuracy of rapid at home PSA tests

www.bbc.co.uk/news/article...

Woohoo! Great work team

@jimcatto.bsky.social

bmjopen.bmj.com/content/bmjo...

Thousands of men in Yorkshire to take part in new prostate screening trial ​​​​​​​Thousands of men in Yorkshire will be offered the opportunity to take part in a new £4.5 million prostate screening trial led by the University of Sheffield.

www.sheffield.ac.uk/news/thousan...

Thousands of men in Yorkshire to take part in new prostate screening trial - Yorkshire Cancer Research Thousands of men in Yorkshire will be offered the opportunity to take part in a new £4.5 million prostate screening trial funded by Yorkshire Cancer Research.

www.yorkshirecancerresearch.org.uk/news/thousan...

Yes.

🏃 Flying start to #IP9ATLAS - first 5️⃣0️⃣ patients recruited!

🔎 Comparing regular MRI scans to standard of care in patients with prostate cancer on active surveillance

🎉 Thank you to our site teams Imperial College Healthcare NHST, Dartford and Gravesham NHST & Frimley Health NHSFT

Can mpMRI replace TURBT for faster treatment in MIBC?
A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social
ascopubs.org/doi/10.1200/JC…

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial PURPOSETransurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatmen...

Great to see this finally out #bladdercancer

ascopubs.org/doi/10.1200/...

Now published: This MA is the basis for our ongoing #ZMoveMent1 study evaluating the impact of endurance*resistance training on QoL, oncological outcomes, fitness in #ProstateCancee pts
👉 we still don’t use #PhysicalExercise in cancer pts in an optimal way
👉 www.mdpi.com/2072-6694/16...

Survival rates for patients with operable bladder cancer significantly improved by immunotherapy before and after surgery ​​​​​​​A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder cancer are significantly improved by adding an immunotherapy drug to b...

www.sheffield.ac.uk/news/surviva...

Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer - OncoDaily Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer / bladder cancer, cancer, event-free survival (EFS), Neal Shore,

Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer

oncodaily.com/insight/sasa...

#BladderCancer #Cancer #EventFreeSurvival #EFS #OncoDaily #Oncology #Pfizer #Sasanlimab

Wow. Great news ... first of a few?

#CREST trial with positive results for #PD-1 in HR #NMIBC!
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social

7. And when diagnosed, black men and those from deprived areas are marginally less likely to receive radical treatment for locally advanced prostate cancer

6. But inequalities persist. Most diagnoses in men from affluent areas (blue) and black men have fewer diagnosis despite much higher risk of having #prostatecancer

5. Similar for large bowel toxicity after radiotherapy

4. Good to see rates of Major Urinary events (i.e. mostly a seciond intervention for (in)continence) are low

3. Good to see 92% of low risk disease being managed with Surveillance

2. Good to see diagnosis rate rising ... still catch up for #COVID-19

Key findings include an increase in men newly diagnosed with prostate cancer: in 2023 in England, a 9% increase when compared to 2022 and a 25% increase compared to 2019. In 2022 in Wales, a 26% increase compared to 2021.

1. The NPCA reports are always a great snap shot of ProstateCancer in England and Wales. Worth checking out for nation wide disease patterns. www.npca.org.uk ..

Huge North-South divide in prostate cancer diagnoses We want to stop prostate cancer being a killer. We fund groundbreaking research, drive improvements in treatment, and fight injustice in care.

Geographic patterns of #prostatecancer reflect awareness, mens health and PSA testing. Big differences exist in the UK and other countries @prostatecanceruk.bsky.social

prostatecanceruk.org/about-us/new...

Credit the authors ... its hard to find defendants of TRUS-Bx in an era of TREXIT. RCTs mostly show equivalence but fewer infections - see www.bmj.com/content/387/... There is loss of equipoise amongst urologists. Patient views under-represented.

www.eu-focus.europeanurology.com/article/S240...

(Over)diagnosis of very low risk #prostatecancer in the USA. The disease that won't go away ..... despite MRI use. Time to abandon random biopsy @dr-coops.bsky.social

euoncology.europeanurology.com/article/S258...

Nice. How to write a Response to reviewers. Amazing how many authors ignore simple questions. Reviewers are usually helping you improve your work.
Well done @vickersbiostats.bsky.social @euplatinum.bsky.social

www.europeanurology.com/article/S030...

2. Nice data. One again show outcomes from #prostatecancer. But avg. age 75 in HIFU cohort and 50% had Gleason 6. Overtreatment common - albeit with less morbid Rx. Confirm need for RCTs @londonprostate1.bsky.social @ip-london.bsky.social @euplatinum.bsky.social @ox.ac.uk @lambalastair.bsky.social

1. HIFU vs Radical prostatectomy non-randomised comparison. Large 1,967 HIFU & 1,361 RP, contemporary 2015-19. 62% intermediate-risk PC. Similar adverse events except long term continence and erectile scores. Less salvage treatments with HIFU.

www.europeanurology.com/article/S030...

Men are being left behind by outdated prostate cancer guidelines. I’ve just signed Prostate Cancer UK’s letter to the Secretary of State for Health and Social Care so that we can improve the outcomes and experience for men in the UK with prostate cancer. Add your n...

I’ve just signed the @prostatecanceruk.bsky.social letter to the Secretary of State for Health and Social Care @rthonwesstreeting.bsky.social asking for simple and free changes to outdated #prostatecancer testing guidelines.

Add your name now - it takes less than a minute!